270 related articles for article (PubMed ID: 2940959)
1. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
[TBL] [Abstract][Full Text] [Related]
2. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
[TBL] [Abstract][Full Text] [Related]
4. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
[TBL] [Abstract][Full Text] [Related]
7. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
8. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
9. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Labrie F; Dupont A; Belanger A; Lacoursiere Y; Raynaud JP; Husson JM; Gareau J; Fazekas AT; Sandow J; Monfette G
Prostate; 1983; 4(6):579-94. PubMed ID: 6415630
[TBL] [Abstract][Full Text] [Related]
10. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
11. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
12. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
13. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
[TBL] [Abstract][Full Text] [Related]
14. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
15. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
Labrie F; Dupont A; Bélanger A; Cusan L; Giguère M; Lacourcière Y; Luthy I; Bégin D; Labrie C; Simard J
Cancer Metastasis Rev; 1987; 6(4):615-36. PubMed ID: 3327635
[TBL] [Abstract][Full Text] [Related]
16. Total androgen ablation: American experience.
Crawford ED; Nabors WL
Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy in advanced prostate cancer.
Forster TH; Stoffel F; Gasser TC
Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
[No Abstract] [Full Text] [Related]
18. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
19. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
[TBL] [Abstract][Full Text] [Related]
20. Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
Labrie F; Dupont A; Bélanger A; St-Arnaud R; Giguère M; Lacourcière Y; Emond J; Monfette G
Endocr Rev; 1986 Feb; 7(1):67-74. PubMed ID: 3514203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]